4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide has been researched along with Parkinsonian Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mabrouk, OS; Marti, M; Morari, M; Volta, M | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Hille, CJ; Maneuf, YP | 1 |
2 other study(ies) available for 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide and Parkinsonian Disorders
| Article | Year |
|---|---|
Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzamides; Bicuculline; Bridged Bicyclo Compounds, Heterocyclic; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; GABA Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Hindlimb Suspension; Male; Microdialysis; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Substantia Nigra; Thiophenes; Time Factors | 2008 |
Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Benzamides; Callithrix; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Male; Motor Activity; Narcotic Antagonists; Parkinsonian Disorders; Piperazines; Posture; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Reserpine | 2001 |